menu
    • menu
    [{"orgOrder":0,"company":"Asahi Kasei Finechem","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"||CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Asahi Kasei Finechem","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asahi Kasei Finechem \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"Asahi Kasei Finechem \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"||CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asahi Kasei Pharma \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Asahi Kasei Pharma \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Isavuconazonium Sulfate","moa":"||CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asahi Kasei Pharma \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Asahi Kasei Pharma \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"||CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asahi Kasei Pharma \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Asahi Kasei Pharma \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"||CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Asahi Kasei Pharma \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Asahi Kasei Pharma \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"||CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Asahi Kasei Pharma \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Asahi Kasei Pharma \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AK1780","moa":"||P2X7 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asahi Kasei Pharma \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Asahi Kasei Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Chiome Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asahi Kasei Pharma \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Asahi Kasei Pharma \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"VectivBio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Apraglutide","moa":"||GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Asahi Kasei Pharma \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Asahi Kasei Pharma \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"VectivBio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Apraglutide","moa":"||GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Asahi Kasei Pharma \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Asahi Kasei Pharma \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"FR104","moa":"||CD28","graph1":"Immunology","graph2":"Phase I","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Asahi Kasei Pharma \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Asahi Kasei Pharma \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Emergent Clinical Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AK1320MS","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asahi Kasei Pharma \/ Emergent Clinical Consulting","highestDevelopmentStatusID":"6","companyTruncated":"Asahi Kasei Pharma \/ Emergent Clinical Consulting"}]

    Find Clinical Drug Pipeline Developments & Deals by Asahi Kasei Pharma

    Menu

    Asahi Kasei Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isavuconazonium Sulfate,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Basilea Pharmaceutica

                            Deal Size : $68.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cresemba Sales in Japan Trigger Second Milestone Payment to Basilea

                            Details : Cresemba, with the active ingredient isavuconazonium sulfate, is an intravenous (i.v.) and oral azole antifungal. Cresemba is marketed in more than 70 countries.

                            Product Name : Cresemba

                            Product Type : Other Small Molecule

                            Upfront Cash : $7.1 million

                            April 24, 2025

                            Lead Product(s) : Isavuconazonium Sulfate,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Basilea Pharmaceutica

                            Deal Size : $68.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isavuconazonium Sulfate,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Basilea Pharmaceutica

                            Deal Size : $68.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cresemba's Japan Launch Triggers Sales Milestone for Basilea

                            Details : Under the terms of the license agreement, Asahi Kasei Pharma is granted an exclusive license to develop and commercialize Cresemba (isavuconazole) in Japan.

                            Product Name : Cresemba

                            Product Type : Other Small Molecule

                            Upfront Cash : $7.19 million

                            February 05, 2025

                            Lead Product(s) : Isavuconazonium Sulfate,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Basilea Pharmaceutica

                            Deal Size : $68.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : Chiome Bioscience

                            Deal Size : $163.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Asahi Kasei Signs Anti-CX3CR1 Antibody License Agreement for Global Reach

                            Details : Under the licensing agreement, Asahi Kasei Pharma has acquired worldwide exclusive rights to develop and commercialize PFKR an anti-CX3CR1 antibody from Chiome.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 20, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : Chiome Bioscience

                            Deal Size : $163.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isavuconazonium Sulfate,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Basilea Pharmaceutica

                            Deal Size : $72.3 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Basilea Announces CHF 5 Million Milestone Payment From Asahi Kasei Pharma For Antifungal Cresemba® (isavucona...

                            Details : Under the terms of the initial agreement, Asahi Kasei Pharma received exclusive rights to develop and commercialize Basilea’s antifungal Cresemba (isavuconazole), an intravenous and oral azole antifungal, in Japan.

                            Product Name : Cresemba

                            Product Type : Other Small Molecule

                            Upfront Cash : $7.5 million

                            March 23, 2023

                            Lead Product(s) : Isavuconazonium Sulfate,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Basilea Pharmaceutica

                            Deal Size : $72.3 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraglutide,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : VectivBio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan

                            Details : Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            March 13, 2023

                            Lead Product(s) : Apraglutide,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : VectivBio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FR104,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : Veloxis Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Inves...

                            Details : VEL-101 (FR104) is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 18, 2022

                            Lead Product(s) : FR104,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : Veloxis Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraglutide,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Recipient : VectivBio

                            Deal Size : $200.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the C...

                            Details : The company entered into agreement with Asahi Kasei Pharma to develop and commercialize apraglutide, a next-generation, long-acting GLP-2 analog, for the treatment of short bowel syndrome with intestinal failure, steroid-refractory acute graft-versus-hos...

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : $30.0 million

                            March 30, 2022

                            Lead Product(s) : Apraglutide,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Recipient : VectivBio

                            Deal Size : $200.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isavuconazonium Sulfate,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Basilea Pharmaceutica

                            Deal Size : $72.3 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Basilea’s Partner Asahi Kasei Pharma Filed New Drug Application For the Marketing Authorization of Isavucona...

                            Details : Under the terms of the agreement, Asahi Kasei Pharma was granted an exclusive license to develop and commercialize isavuconazole in Japan.

                            Product Name : Cresemba

                            Product Type : Other Small Molecule

                            Upfront Cash : $7.5 million

                            September 30, 2021

                            Lead Product(s) : Isavuconazonium Sulfate,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Basilea Pharmaceutica

                            Deal Size : $72.3 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Asahi Kasei Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isavuconazonium Sulfate,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Basilea Pharmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Basilea’s Partner Asahi Kasei Pharma Prepares NDA Filing for the Marketing Authorization of Isavuconazole in...

                            Details : The phase 3, multi-center, open-label study enrolled 103 patients and was assessing the safety and efficacy of intravenously or orally administered isavuconazole for the treatment of adult Japanese patients suffering from deep-seated mycoses.

                            Product Name : Cresemba

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 26, 2021

                            Lead Product(s) : Isavuconazonium Sulfate,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Basilea Pharmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Asahi Kasei Finechem

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Asahi Kasei Finechem

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isavuconazonium Sulfate,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Basilea’s Partner Asahi Kasei Pharma Completes Patient Enrolment in Phase 3 Study with Antifungal Isavuconaz...

                            Details : The phase 3 study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.

                            Product Name : Cresemba

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 01, 2021

                            Lead Product(s) : Isavuconazonium Sulfate,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth